Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > New all time low at 0.04 cad?
View:
Post by Turtle4 on Jun 28, 2024 12:06pm

New all time low at 0.04 cad?

Congratulation. What a transformational year!
Comment by Pareto8020 on Jun 28, 2024 1:39pm
It takes a special kind of stupid to sign a contract with a major pharma and then run your stock price into the ground.  Congrat's Howie - you show them how its done!
Comment by bealert on Jun 28, 2024 2:02pm
Happy to report that the all time low was about 12 years ago @ 3 cents.  So 4 cents is 33.333333% better than 3 cents.  WOW. Last trade was at 5 cents so that's an incredible increase from 3 cents! Good luck to all as we march to the drug store for more ulcer medication, thanks to honest howey, and all of those who helped him sucker us. BeAlert
Comment by Turtle4 on Jun 28, 2024 5:29pm
In fact, I only checked the 10-year chart.... But you can see from the chart: History repeats itself. So let's wait for the next spike and this time really sell before everything collapses again.
Comment by MirrorWorldMan on Jun 29, 2024 12:02pm
We are at a worthless penny stock at this point.  Only a buyout or tangible expectation of revenue will help.  Howie needs to stop with this, "we are pleased to report..." alpo and present NR about the AbbVie deal. 
Comment by Turtle4 on Jul 01, 2024 3:29pm
Insiders often buy when the share price has fallen so sharply. On the one hand to exude confidence, or simply to make good money if they are convinced that things will go up again. Unfortunately, neither is the case here... And I don't believe that insider information prohibits them from trading. Abbvie will probably only let you know after the official release.
Comment by Pandora on Jul 01, 2024 8:22pm
And I still wonder why Abbvie leaves the Sirona/TF Chem product sitting on the shelf and not releasing it into the market. Are they, in effect, controlling the market for their existing products until such time as they feel it will be a more opportune time to finally put the new product into the marketplace. i.e. they keep making money on existing product while we as shareowners have to sit back ...more  
Comment by Pandora on Jul 01, 2024 10:56pm
Just as a refresher  re my previous post: It was in October 2021 that it was announced they were in discussions with a major company. In December it was announced that they had hired Linda Pullan of Pullan Consulting to negotiate with this major cosmetic company. It was in June of 2022 that it was announced that an agreement had been signed with Allergen Aesthetics, a division of Abbvie ...more  
Comment by Pandora on Jul 01, 2024 11:01pm
I don't remember seeing a clause that said it would be a minimum of 2 years or longer before a product launch would happen or that all interval payments would not start until the "Launch" happened.
Comment by Turtle4 on Jul 03, 2024 2:27am
Linda did a great job. She has negotiated such high royalties that it is no longer worthwhile for Allergan and they are focusing on their own products instead. After all, tfc1067 is off the market. Allergan is paying the small contractual penalty out of its petty cash.
Comment by Pareto8020 on Jul 03, 2024 11:47am
It's definitely a head scratcher that they haven't even reached the point of having to pay a milestone.   Another fantastic deal by Howard with zero details, next to zero upfront payment and zero royalties paid to date. No way Howard anticipated Allergan taking this long to incorporate their compound into their lineup.  He never learns his lesson and us shareholders are the ...more  
Comment by SleepyHoward on Jul 03, 2024 12:35pm
So true
Comment by Pareto8020 on Jul 03, 2024 7:21pm
Anyone recall the PRC breakdown that appeared to use Sirona fonts and graphics so one could infer it was a way for the company to promote themselves via a third party? https://57ea05b9-8ae7-4fa0-b2d8-87d70d135d8c.usrfiles.com/ugd/57ea05_4dfabf8ca3aa4f9e929d16bcfcc954dd.pdf   Some of the highlights seem humorous now that a couple years have shot by: "We estimate that AbbVie will ...more  
Comment by lscfa on Jul 03, 2024 8:31pm
I don't know what PRC got for that pump but they should have got life.
Comment by Turtle4 on Jul 04, 2024 3:47am
I think the PRC figures would be quite realistic if the license went to a global cosmetics company. Skinmedica is only really represented in North America. The large skin lightening market will probably not be penetrated but only the high-priced dark spot market (ethical requirements...) and that is only a small fraction of the market.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities